ebola; epidemic; evd; ebov

Basler CF, Mikulasova A, Martinez-Sobrido L, Paragas J, Muhlberger E, Bray M, Klenk HD, Palese P & Garcia-Sastre A 2003 The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol 77 7945-7956

Basler CF, Wang X, Muhlberger E, Volchkov V, Paragas J, Klenk HD, Garcia-Sastre A & Palese P 2000 The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A 97 12289-12294

Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB, Ksiazek T, Johnson KM, Meyerhoff A, O'Toole T, Ascher MS, Bartlett J, Breman JG, Eitzen EM Jr, Hamburg M, Hauer J, Henderson DA, Johnson RT, Kwik G, Layton M, Lillibridge S, Nabel GJ, Osterholm MT, Perl TM, Russell P, Tonat K & Working Group on Civilian Biodefense 2002 Hemorrhagic fever viruses as biological weapons: Medical and public health management. JAMA 287 2391-2405

Bwaka MA, Bonnet MJ, Calain P, Colebunders R, De Roo A, Guimard Y, Katwiki KR, Kibadi K, Kipasa MA, Kuvula KJ, Mapanda BB, Massamba M, Mupapa KD, Muyembe-Tamfum JJ, Ndaberey E, Peters CJ, Rollin PE, Van den Enden E & Van den Enden E 1999 Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis 179 S1-7

Cardenas WB, Loo YM, Gale M Jr, Hartman AL, Kimberlin CR, Martinez-Sobrido L, Saphire EO & Basler CF 2006 Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signalling. J Virol 80 5168-5178

Carvalho CS, Vlachakis D, Tsiliki G, Megalooikonomou V & Kossida S 2013 Protein signatures using electrostatic molecular surfaces in harmonic space PeerJ 1 e185

Cote M, Misasi J, Ren T, Bruchez A, Lee K, Filone CM, Hensley L, Li Q, Ory D, Chandran K & Cunningham J 2011 Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 477 344-348

Dalkas GA, Vlachakis D, Tsagkrasoulis D, Kastania A & Kossida S 2013 State-of-the-art technology in modern computer-aided drug design. Brief Bioinform 14 745-752

Dowell SF, Mukunu R, Ksiazek TG, Khan AS, Rollin PE & Peters CJ 1999 Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 179 S87-91

Fowler RA, Fletcher T, Fischer WA 2nd, Lamontagne F, Jacob S, Brett-Major D, Lawler JV, Jacquerioz FA, Houlihan C, O'Dempsey T, Ferri M, Adachi T, Lamah MC, Bah EI, Mayet T, Schieffelin J, McLellan SL, Senga M, Kato Y, Clement C, Mardel S, Vallenas Bejar De Villar RC, Shindo N & Bausch D 2014 Caring for critically ill patients with ebola virus disease. Perspectives from west Africa. Am J Respir Crit Care Med 190 733-737

Francesconi P, Yoti Z, Declich S, Onek PA, Fabiani M, Olango J, Andraghetti R, Rollin PE, Opira C, Greco D & Salmaso S 2003 Ebola hemorrhagic fever transmission and risk factors of contacts, Uganda. Emerg Infect Dis 9 1430-1437

Gire SK, Goba A, Andersen KG, Sealfon RS, Park DJ, Kanneh L, Jalloh S, Momoh M, Fullah M, Dudas G, Wohl S, Moses LM, Yozwiak NL, Winnicki S, Matranga CB, Malboeuf CM, Qu J, Gladden AD, Schaffner SF, Yang X, Jiang PP, Nekoui M, Colubri A, Coomber MR, Fonnie M, Moigboi A, Gbakie M, Kamara FK, Tucker V, Konuwa E, Saffa S, Sellu J, Jalloh AA, Kovoma A, Koninga J, Mustapha I, Kargbo K, Foday M, Yillah M, Kanneh F, Robert W, Massally JL, Chapman SB, Bochicchio J, Murphy C, Nusbaum C, Young S, Birren BW, Grant DS, Scheiffelin JS, Lander ES, Happi C, Gevao SM, Gnirke A, Rambaut A, Garry RF, Khan SH & Sabeti PC 2014 Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science 345 1369-1372

Gomes MFC, Pastore y Piontti A, Rossi L, Chao D, Longini I, Halloran ME & Vespignani A 2014 Assessing the International Spreading Risk Associated with the 2014 West African Ebola Outbreak. PLOS Cur Outbreak Edition 1

Groseth A, Feldmann H & Strong JE 2007 The ecology of Ebola virus. Trends Microbiol 15 408-416

Gulland A 2014 Spanish authorities investigate how nurse contracted Ebola. BMJ 349 g6120

Huang Y, Xu L, Sun Y & Nabel GJ 2002 The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein Mol Cell 10 307-316

Jaax N, Jahrling P, Geisbert T, Geisbert J, Steele K, McKee K, Nagley D, Johnson E, Jaax G & Peters C 1995 Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet 346 1669-1671

Kuhn JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, Kawaoka Y, Lipkin WI, Negredo AI, Netesov SV, Nichol ST, Palacios G, Peters CJ, Tenorio A, Volchkov VE & Jahrling PB 2010 Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations Arch Virol 155 2083-2103

Leung DW, Prins KC, Borek DM, Farahbakhsh M, Tufariello JM, Ramanan P, Nix JC, Helgeson LA, Otwinowski Z, Honzatko RB, Basler CF & Amarasinghe GK 2010 Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat Struct Mol Biol 17 165-172

Loukatou S, Papageorgiou L, Fakourelis P, Filtisi A, Polychronidou E, Bassis I, Megalooikonomou V, Makalowski W, Vlachakis D & Kossida S 2014 Molecular dynamics simulations through GPU video games technologies. J Mol Biochem 3 64-71

McCarthy M 2014 Liberian man being treated for Ebola in Texas dies. BMJ 349 g6145

Miller J, Engelberg S & Broad WJ 2002 Germs: Biological Weapons and America's Secret War: Simon & Schuster

Muyembe-Tamfum JJ, Kipasa M, Kiyungu C & Colebunders R 1999 Ebola outbreak in Kikwit, Democratic Republic of the Congo: discovery and control measures. J Infect Dis 179 S259-262

Nagata N 2014 International Control of Epidemic Diseases from a Historical and Cultural Perspective. In M. Herren, ed, Networking the International System, pp. 73-88. Springer International Publishing.

Prevention, C. f. D. C. a. (October 13, 2014). Outbreaks Chronology: Ebola Virus Disease.

Papangelopoulos N, Vlachakis D, Filtisi A, Fakourelis P, Papageorgiou L, Megalooikonomou V & Kossida S 2014 State of the art GPGPU applications in bioinformatics Int J Sys Biol Biomed Tech 2 24-48

Papageorgiou L, Vlachakis D, Koumandou VL, Papagelopoulos N & Kossida S 2014 Computer-aided drug design and biological evaluation of novel anti-Greek goat encephalitis agents. Int J Sys Biol Biomed Tech 2 1-16

Salvaggio MR & Baddley JW 2004 Other viral bioweapons: Ebola and Marburg hemorrhagic fever. Dermatol Clin 22 291-302

Sellis D, Vlachakis D & Vlassi M 2009 Gromita: a fully integrated graphical user interface to gromacs 4. Bioinform Biol Ins 3 99-102

Sullivan NJ, Hensley L, Asiedu C, Geisbert TW, Stanley D, Johnson J, Honko A, Olinger G, Bailey M, Geisbert JB, Reimann KA, Bao S, Rao S, Roederer M, Jahrling PB, Koup RA & Nabel GJ 2011 CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med 17 1128-1131

Tigabu B, Juelich T, Bertrand J & Holbrook MR 2009 Clinical evaluation of highly pathogenic tick-borne flavivirus infection in the mouse model. J Med Virol 81 1261-1269

Vangelatos I, Vlachakis D, Sophianopoulou V & Diallinas G 2009 Modelling and mutational evidence identify the substrate binding site and functional elements in APC amino acid transporters. Mol Membrane Biol 26 356-370

Vlachakis D, Bencurova E, Papangelopoulos N & Kossida S 2014 Current State-of-the-Art Molecular Dynamics Methods and Applications. Adv Protein Chem Struct Biol 94 269-313

Vlachakis D & Kossida S 2013 Molecular modeling and pharmacophore elucidation study of the Classical Swine Fever virus helicase as a promising pharmacological target. PeerJ 1 e85

Vlachakis D, Pavlopoulou A, Roubelakis MG, Feidakis C, Anagnou NP & Kossida S 2014 3D molecular modeling and evolutionary study of the Trypanosoma brucei DNA Topoisomerase IB, as a new emerging pharmacological target. Genomics 103 107-113.